Legato Capital Management LLC Buys New Holdings in IDEAYA Biosciences, Inc. $IDYA

Legato Capital Management LLC bought a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 23,900 shares of the company’s stock, valued at approximately $826,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Arizona State Retirement System increased its position in IDEAYA Biosciences by 1.5% in the 3rd quarter. Arizona State Retirement System now owns 23,324 shares of the company’s stock valued at $635,000 after buying an additional 353 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its position in IDEAYA Biosciences by 49.4% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after buying an additional 380 shares in the last quarter. Daiwa Securities Group Inc. increased its position in IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after buying an additional 436 shares in the last quarter. PNC Financial Services Group Inc. increased its position in IDEAYA Biosciences by 16.1% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,881 shares of the company’s stock valued at $106,000 after buying an additional 537 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its position in IDEAYA Biosciences by 171.1% in the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after buying an additional 580 shares in the last quarter. 98.29% of the stock is owned by institutional investors.

Insider Buying and Selling at IDEAYA Biosciences

In other news, Director Jeffrey Stein acquired 50,000 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were acquired at an average price of $32.96 per share, for a total transaction of $1,648,000.00. Following the completion of the purchase, the director owned 54,281 shares in the company, valued at approximately $1,789,101.76. This trade represents a 1,167.95% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.70% of the stock is owned by insiders.

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA opened at $29.10 on Tuesday. IDEAYA Biosciences, Inc. has a twelve month low of $18.25 and a twelve month high of $39.28. The stock’s 50 day moving average price is $30.87 and its 200-day moving average price is $32.79. The company has a market capitalization of $2.56 billion, a PE ratio of -18.19 and a beta of -0.04.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The firm had revenue of $6.56 million during the quarter, compared to analysts’ expectations of $5.04 million. During the same quarter in the previous year, the firm earned ($0.82) EPS. The firm’s revenue was down 39.4% on a year-over-year basis. As a group, research analysts expect that IDEAYA Biosciences, Inc. will post -4.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on IDYA shares. Mizuho decreased their price objective on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Royal Bank Of Canada boosted their price objective on IDEAYA Biosciences from $49.00 to $53.00 and gave the stock an “outperform” rating in a report on Tuesday, April 14th. The Goldman Sachs Group boosted their price objective on IDEAYA Biosciences from $31.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, April 14th. Wells Fargo & Company boosted their price objective on IDEAYA Biosciences from $44.00 to $48.00 and gave the stock an “overweight” rating in a report on Tuesday, April 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Tuesday, April 21st. Fifteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $50.69.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.